Claims for Patent: 5,830,727

Summary for Patent: 5,830,727

Title:	Herpes simplex virus amplicon mini-vector gene transfer system
Abstract:	A novel HSV mini viral vector is disclosed. The vector comprises HSV and EBV genes which allow it to remain in episomal state, to have very high transfection and infection, and to tolerate up to 140 kb of foreign DNA. Techniques and genetic constructs for producing the vectors, for constructing the vectors and transfection and infection to recipient cells are disclosed.
Inventor(s):	Wang; Suming (Des Moines, IA), Link, Jr.; Charles J. (Des Moines, IA)
Assignee:	Human Gene Therapy Research Institute (Des Moines, IA)
Application Number:	08/578,500
Patent Claims:	1. A recombinant mini-viral Herpes Simplex Virus vector comprising: a replication origin, "ori S" from Herpes Simplex Virus; an Herpes Simplex Virus packaging sequence "a"; an Epstein-Barr Virus nuclear antigen gene "EBNA-1"; and an Epstein-Barr Virus latent origin of replication "ori P". 2. The vector of claim 1 further comprising: procaryotic genes for propagation of said vector in E. coli. 3. The vector of claim 1 further comprising prokaryotic genes for Hygromycin resistance, or the eukaryotic gene MDR-1. 4. The vector of claim 1 further comprising a transcription unit for expression of a nucleotide sequence the expression of which is desired in a cell. 5. The vector of claim 2 wherein said E. coli genes include a col E1 ori gene. 6. The vector of claim 5 further comprising a selectable marker gene for propagation in E. coli. 7. The vector of claim 6 wherein said selectable marker gene is selected from the group consisting of an ampicillin resistance gene, kanamycin resistance gene, tetracycline resistance gene and zeocin resistance gene. 8. The vector of claim 3 wherein said Hygromycin resistance gene is flanked on one end with a promoter regulator region and on the other with a transcription termination signal. 9. The vector of claim 8 wherein said promoter is the Herpes Simplex Virus thymidine kinase promoter and said transcription termination signal is the Herpes Simplex Virus thymidine kinase polyadenylation signal. 10. The vector of claim 4 wherein said transcription unit comprises a foreign gene to be expressed, a promoter and a polyadenylation site. 11. The vector of claim 4 wherein said transcription unit comprises a gene with its native regulator elements, its exon and intron regions and its termination signal. 12. The vector of claim 4 wherein said nucleotide sequence is the cDNA which encodes Duchennes muscular dystrophy. 13. The transcription unit of claim 4 comprising a promoter selected from the group consisting of an inducible promoter, a tissue specific promoter and an artificial promoter enhancer. 14. The transcription unit of claim 10 wherein said promoter is selected from the group consisting of the cytomegalovirus promoter early promoter and the Rous sarcoma virus long terminal repeat, and wherein said polyadenylation site is the SV40 polyadenylation site. 15. The vector of claim 14 wherein said vector includes a multiple cloning site. 16. The vector of claim 15 wherein said multiple cloning site is the multiple cloning site depicted in FIG. 1. 17. A method for producing recombinant HSV/EBV viral particles comprising the steps of: (a) introducing into a helper cell line an HSV/EBV vector comprising the package cleavage signal sequence from HSV, a replication origin ori S from HSV, an EBNA-1 gene from Epstein-Barr Virus and an ori P gene from Epstein-Barr Virus; (b) growing said helper cell line in a cell growth medium; and (c) inducing virion propagation by introducing a complementing Herpes Simplex Virus .DELTA.IE3 helper virus to said cell line so that recombinant HSV/EBV viral particles are produced. 18. The method of claim 17 wherein said helper cell line expresses the HSV IE3 gene, and said helper virus is a HSV .DELTA.IE3 mutant. 19. The method of claim 17 wherein said vector further comprises: procaryotic genes for hygromycin resistance. 20. The method of claim 19 further comprising the step of: selecting for hygromycin resistance prior to inducing virion propagation. 21. A cell line transfected with HSV/EBV plasmid vector, said HSV/EBV plasmid vector comprising: an Epstein-Barr Virus nuclear antigen gene, an Epstein-Barr Virus latent origin of replication, a Herpes Simplex Virus package cleavage signal, and a replication origin "ori S" from Herpes Simplex Virus. 22. The cell line of claim 21 wherein said cell line expresses an IE3 Herpes Simplex Virus gene and comprises a HSV helper virus. 23. The cell line of claim 22 wherein cell line expresses the Epstein-Barr virus EBNA-1gene. 24. The cell line of claim 22 wherein said helper virus is a IE gene deletion mutant which is complemented by said cell line. 25. The cell line of claim 24 wherein said HSV helper virus is a .DELTA.IE3 mutant. 26. The cell line of claim 23 wherein said HSV/EBV plasmid vector omits the EBNA-1 gene. 27. A recombinant mini-viral Herpes Simplex Virus vector comprising: a replication origin, "ori S" from Herpes Simplex Virus; an Herpes Simplex Virus packaging sequence "A"; and a second viral sequence which allows the vector to be maintained in episomal form. 28. The vector of claim 27 wherein said second viral sequence is selected from the group consisting of Epstein-Barr virus, bovine papillomavirus and human papillomavirus. 29. The vector of claim 27 further comprising a reporter gene. 30. The vector of claim 27 further comprising a transgene. 31. The vector of claim 27 further comprising fusion genes. 32. The vector of claim 27 further comprising multiple genes. 33. A plasmid HSV mini-viral, said vector selected from the group consisting of pHE700; pHE750; pHE500, pHE550, pHE650; pHE400, and pHE450.

Details for Patent 5,830,727

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26